Format

Send to

Choose Destination
Cell. 2015 Feb 12;160(4):729-744. doi: 10.1016/j.cell.2015.01.028.

MEK guards proteome stability and inhibits tumor-suppressive amyloidogenesis via HSF1.

Author information

1
The Jackson Laboratory, 600 Main Street, Bar Harbor, ME 04609, USA; Graduate Programs, Department of Molecular and Biomedical Sciences, The University of Maine, 5735 Hitchner Hall, Orono, ME 04469, USA.
2
The Jackson Laboratory, 600 Main Street, Bar Harbor, ME 04609, USA.
3
The Jackson Laboratory, 600 Main Street, Bar Harbor, ME 04609, USA. Electronic address: chengkai.dai@jax.org.

Abstract

Signaling through RAS/MAP kinase pathway is central to biology. ERK has long been perceived as the only substrate for MEK. Here, we report that HSF1, the master regulator of the proteotoxic stress response, is a new MEK substrate. Beyond mediating cell-environment interactions, the MEK-HSF1 regulation impacts malignancy. In tumor cells, MEK blockade inactivates HSF1 and thereby provokes proteomic chaos, presented as protein destabilization, aggregation, and, strikingly, amyloidogenesis. Unlike their non-transformed counterparts, tumor cells are particularly susceptible to proteomic perturbation and amyloid induction. Amyloidogenesis is tumor suppressive, reducing in vivo melanoma growth and contributing to the potent anti-neoplastic effects of proteotoxic stressors. Our findings unveil a key biological function of the oncogenic RAS-MEK signaling in guarding proteostasis and suppressing amyloidogenesis. Thus, proteomic instability is an intrinsic feature of malignant state, and disrupting the fragile tumor proteostasis to promote amyloidogenesis may be a feasible therapeutic strategy.

PMID:
25679764
PMCID:
PMC4564124
DOI:
10.1016/j.cell.2015.01.028
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center